Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin LtdfiledCriticalTeijin Ltd
Priority to JP5798679ApriorityCriticalpatent/JPS55151590A/en
Publication of JPS55151590ApublicationCriticalpatent/JPS55151590A/en
NEW MATERIAL:The title compound shown by the formula I (R is lower alkyl, lower alkoxy, or halogen; n is 0 or 1W4; B and C rings are cis or trans form).
USE: A drug useful for treatment of cancer and autoimmune disease, e.g., rheumatoid arthritis having immuization or immunosuppression.
PROCESS: A tetrahydronaphtho[1,2-d]imidazoline-2-thione is reacted with a compound shown by the formula [Y or Z is halogen, arylsulfonyloxy or alkanesulfonyloxy) to give a compound shown by the formula I. The compound shown by the formula II is also novel one.
COPYRIGHT: (C)1980,JPO&Japio
JP5798679A1979-05-141979-05-14Hexahydronaphtho(2',1':4,5)imidazo(2,1-b)thiazole and its preparation
PendingJPS55151590A
(en)